Mesoblast (MESO) Other financing activities (2017 - 2018)

Mesoblast's (MESO) quarterly Other financing activities came in at -$409000.0 in Q2 2018, up 24.68% quarter-over-quarter from -$543000.0 in Q3 2017.

Mesoblast (MESO) Other financing activities (2017 - 2018) Analysis & Trends

Mesoblast has disclosed Other financing activities across 2 years of filings, most recently posting -$409000.0 for Q2 2018.

Other financing activities for Q2 2018 came in at -$409000.0, changed N/A year-over-year; the trailing twelve-month figure through Jun 2018 was -$952000.0 (changed N/A YoY), and the FY2020 annual result was -$1.0 million, down 42.44% from the prior year.
Other financing activities came in at -$409000.0 for Q2 2018 at Mesoblast, up from -$543000.0 in the prior quarter.
In the past five years, Other financing activities ranged from a high of -$409000.0 in Q2 2018 to a low of -$543000.0 in Q3 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Mesoblast	21.68 Bn	21.55 Bn	-

Download Data